Literature DB >> 12165855

Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour.

Dominique Baudry1, Marine Faussillon, Marie-Odile Cabanis, Muriel Rigolet, Jean-Michel Zucker, Catherine Patte, Sabine Sarnacki, Liliane Boccon-Gibod, Claudine Junien, Cécile Jeanpierre.   

Abstract

Wilms' tumour (WT) or nephroblastoma is the most frequent kidney cancer in children. In a previous study, we reported alterations to WT1 transcription in 90% of WT tested, with decreased exon 5 +/- isoform ratio being the most frequent alteration (56% of WT). We now report an approach based on cDNA profiling of tumour pools to identify genes likely to be dysregulated in association with a decreased WT1 exon 5 +/- ratio. We compared the expression profiles of pools of tumours classified according to whether this isoform imbalance was present (five tumours) or not (four tumours), using Atlas Cancer cDNA expression arrays. Fourteen of 588 genes tested displayed specific up-regulation (CCND2, PCNA, N-MYC, E2F3, TOP2A, PAK1, DCC and PCDH2) or down-regulation (VEGF, IGFBP5, TIMP3, ARHB, C-FOS and CD9) in the pool of tumours with decreased exon 5 +/- ratio. These results were validated by RT-PCR analysis of four genes (CCND2, PCNA, VEGF and IGFBP5). We extended the analysis of VEGF expression to 51 tumours by real-time RT-PCR and ascertained differential expression of this gene associated with WT1 expression pattern. Moreover, our results suggest that the VEGF expression level may be of prognosis relevance for relapsed patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165855     DOI: 10.1038/sj.onc.1205752

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Emerging roles of BRCA1 alternative splicing.

Authors:  T I Orban; E Olah
Journal:  Mol Pathol       Date:  2003-08

2.  Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells.

Authors:  Kylie Graham; Wenliang Li; Bryan R G Williams; Gail Fraizer
Journal:  Gene Expr       Date:  2006

Review 3.  Aberrant RNA splicing and its functional consequences in cancer cells.

Authors:  James D Fackenthal; Lucy A Godley
Journal:  Dis Model Mech       Date:  2008 Jul-Aug       Impact factor: 5.758

4.  Regulation of intracellular Zn homeostasis in two intestinal epithelial cell models at various maturation time points.

Authors:  Eva-Maria Gefeller; Angelika Bondzio; Jörg R Aschenbach; Holger Martens; Ralf Einspanier; Franziska Scharfen; Jürgen Zentek; Robert Pieper; Ulrike Lodemann
Journal:  J Physiol Sci       Date:  2015-03-11       Impact factor: 2.781

5.  Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.

Authors:  Julie Hanson; Jacquelyn Gorman; Jennifer Reese; Gail Fraizer
Journal:  Front Biosci       Date:  2007-01-01

6.  GCOD - GeneChip Oncology Database.

Authors:  Fenglong Liu; Joseph A White; Corina Antonescu; Daniel Gusenleitner; John Quackenbush
Journal:  BMC Bioinformatics       Date:  2011-02-03       Impact factor: 3.169

7.  The Wilms' Tumor Gene WT1 - 17AA/- KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model.

Authors:  Keiko Yamanouchi; Tsuyoshi Ohta; Zhiyang Liu; Yusuke Oji; Haruo Sugiyama; Viji Shridhar; Sohei Matsumura; Toshifumi Takahashi; Kazuhiro Takahashi; Hirohisa Kurachi
Journal:  Transl Oncol       Date:  2014-10-24       Impact factor: 4.243

8.  A genome-wide association study identifies four novel susceptibility loci underlying inguinal hernia.

Authors:  Eric Jorgenson; Nadja Makki; Ling Shen; David C Chen; Chao Tian; Walter L Eckalbar; David Hinds; Nadav Ahituv; Andrew Avins
Journal:  Nat Commun       Date:  2015-12-21       Impact factor: 14.919

Review 9.  Transcription Factors in Cancer: When Alternative Splicing Determines Opposite Cell Fates.

Authors:  Silvia Belluti; Giovanna Rigillo; Carol Imbriano
Journal:  Cells       Date:  2020-03-20       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.